Autolus Therapeutics (NASDAQ:AUTL) Trading 6.3% Higher - Still a Buy?

Key Points

• AUTL shares rose 6.3% to $2.285 in Monday trading, although volume was 78% below the stock’s average daily level.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and a $10.00 average price target, substantially above the current share price.
• Autolus beat quarterly expectations, reporting a loss of $0.15 per share versus the $0.21 expected and revenue of $45.69 million versus $38.56 million estimated. However, the company remains deeply unprofitable, with a negative net margin of 238.66%.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) traded up 6.3% during trading on Monday . The stock traded as high as $2.25 and last traded at $2.2850. 381,911 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 1,748,486 shares. The stock had previously closed at $2.15.

Wall Street Analysts Forecast Growth

AUTL has been the topic of several research analyst reports. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a "strong-buy" rating in a research note on Monday, April 20th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Weiss Ratings raised shares of Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday. Finally, Wall Street Zen upgraded shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Autolus Therapeutics Stock Performance

The company has a market cap of $605.51 million, a P/E ratio of -2.15 and a beta of 2.07. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The business has a fifty day simple moving average of $1.64 and a two-hundred day simple moving average of $1.57.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The firm had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. On average, sell-side analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.8 EPS for the current year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AUTL. GAMMA Investing LLC raised its stake in Autolus Therapeutics by 115.6% during the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock valued at $25,000 after purchasing an additional 8,309 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in Autolus Therapeutics by 2.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company's stock valued at $722,000 after buying an additional 11,197 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company's stock valued at $88,000 after buying an additional 11,289 shares in the last quarter. Invesco Ltd. raised its position in shares of Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after buying an additional 11,381 shares during the last quarter. Finally, Marex Group plc bought a new stake in shares of Autolus Therapeutics during the second quarter valued at approximately $28,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source